1. Go AS et al. The New England Journal of Medicine. 2004;351(13):1296–1305.

2. Chronic Kidney Disease Prognosis Consortium. Lancet. 2010;375(9731):2073–2081.

3. Ndumele CE, et al. Circulation. 2023;148(20):1606–1635.

4. Sumida K et al. Clinical Journal of the American Society of Nephrology. 2017;12(12):1941–1949.

ACR, albumin-creatinine ratio

AE, adverse event

AESI, adverse event of special interest

AF, atrial fibrillation

AMD, adjusted mean difference

AUC, area under the curve

BNP, B-type natriuretic peptide

CI, confidence interval

CKD, chronic kidney disease

CV, cardiovascular

CVD, cardiovascular disease

DM, diabetes mellitus

ECG, electrocardiogram

eGFR, estimated glomerular filtration rate

ESC, European Society of Cardiology

Hb, hemoglobin

HF, heart failure

HFA, Heart Failure Association

HFpEF, heart failure with preserved ejection fraction

HFrEF, heart failure with reduced ejection fraction

HR, hazard ratio

HTN, hypertension

KDIGO, Kidney Disease: Improving Global Outcomes

LV, left ventricle

MACE, major adverse cardiovascular events

MI, myocardial infarction

MRA, mineralocorticoid receptor antagonist

NSTEMI, non-ST-segment elevation myocardial infarction

NT-proBNP, N-terminal pro B-type natriuretic peptide

OD, once daily

OMI, occlusion myocardial infarction

PAD, peripheral artery disease

RASi, renin-angiotensin system inhibitors

SAE, serious adverse event

SGLT2i, sodium-glucose cotransporter 2 inhibitor

SOC, standard of care

SR, sinus rhythm

STEMI, ST-segment elevation myocardial infarction

UK, United Kingdom

US, United States